Cargando…

Proton Pump Inhibitors in IPF: A Call for Clinical Trials

The recent FDA approval of two drugs, pirfenidone and nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF) has fueled interest in the development of additional drugs to treat the disease or its major clinical complications including cough and acute exacerbations. Since 2015, there ar...

Descripción completa

Detalles Bibliográficos
Autor principal:	Ghebre, Yohannes T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966555/ https://www.ncbi.nlm.nih.gov/pubmed/29867501 http://dx.doi.org/10.3389/fphar.2018.00499

Ejemplares similares

Proton Pump Inhibitors and Osteoporosis: Is Collagen a Direct Target?
por: Ghebre, Yohannes T.
Publicado: (2020)

Proton pump inhibitors and sensitization of cancer cells to radiation therapy
por: Hebert, Kassidy A., et al.
Publicado: (2022)

Proton Pump Inhibitors and Cancer: Current State of Play
por: Bridoux, Marie, et al.
Publicado: (2022)

Clinical Intervention Increases Rational Use of Proton Pump Inhibitors in the General Surgery Department
por: Chen, Qiying, et al.
Publicado: (2022)

Proton-pump inhibitor use amongst patients with severe hypomagnesemia
por: Seah, Sherry, et al.
Publicado: (2023)

A Narrative Review on Efficacy and Safety of Proton Pump Inhibitors in Children
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma Cells
por: Chueca, Eduardo, et al.
Publicado: (2016)

IPF-Acute Exacerbations: Advances and Future Perspectives
por: Papiris, Spyros A., et al.
Publicado: (2022)

Proton Pump Inhibitors and Serum Magnesium Levels in Patients With Torsades de Pointes
por: Lazzerini, Pietro E., et al.
Publicado: (2018)

Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapy
por: Ikemura, Kenji, et al.
Publicado: (2017)

Correlation of Proton Pump Inhibitors with Pulmonary Tuberculosis: A Case-Control Study in Taiwan
por: Cheng, Kao-Chi, et al.
Publicado: (2017)

Association Between Proton Pump Inhibitors and Asthma: A Population-Based Cohort Study
por: Wang, Yao-Tung, et al.
Publicado: (2020)

Clinical Outcomes of Concomitant Use of Proton Pump Inhibitors and Dual Antiplatelet Therapy: A Systematic Review and Meta-Analysis
por: Guo, Hongzhou, et al.
Publicado: (2021)

Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and Characteristics
por: Matuz, Mária, et al.
Publicado: (2020)

Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota
por: Tian, Liang, et al.
Publicado: (2023)

Association Between Cholangiocarcinoma and Proton Pump Inhibitors Use: A Nested Case-Control Study
por: Peng, Yen-Chun, et al.
Publicado: (2018)

When does proton pump inhibitor treatment become long term? A scoping review
por: Haastrup, Peter Fentz, et al.
Publicado: (2021)

The Influence of CYP3A4 Genetic Polymorphism and Proton Pump Inhibitors on Osimertinib Metabolism
por: Gao, Nanyong, et al.
Publicado: (2022)

A Prescribing Cascade of Proton Pump Inhibitors Following Anticholinergic Medications in Older Adults With Dementia
por: Trenaman, Shanna C., et al.
Publicado: (2022)

Inhibition of Tryptophan Hydroxylases and Monoamine Oxidase-A by the Proton Pump Inhibitor, Omeprazole—In Vitro and In Vivo Investigations
por: Betari, Nibal, et al.
Publicado: (2020)

The Association Between Proton Pump Inhibitors and COVID-19 is Confounded by Hyperglycemia in a Population-Based Study
por: Shafrir, Asher, et al.
Publicado: (2022)

Proton Pump Inhibitors Were Associated With Reduced Pseudocysts in Acute Pancreatitis: A Multicenter Cohort Study
por: Zhang, Shengyu, et al.
Publicado: (2021)

Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis
por: Guo, Huizhu, et al.
Publicado: (2023)

Evaluating physicians’ awareness and prescribing trends regarding proton pump inhibitors: a cross-sectional study
por: Swed, Sarya, et al.
Publicado: (2023)

Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study
por: Kang, Jieun, et al.
Publicado: (2023)

Using proton pump inhibitors increases the risk of hepato-biliary-pancreatic cancer. A systematic review and meta-analysis
por: Zhou, Wence, et al.
Publicado: (2022)

Do proton pump inhibitors affect the effectiveness of chemotherapy in colorectal cancer patients? A systematic review with meta-analysis
por: Lin, Wan-Ying, et al.
Publicado: (2022)

Effectiveness of vonoprazan-based regimens compared with proton pump inhibitor-based regimens as first-line Helicobacter pylori agents
por: Kakiuchi, Toshihiko
Publicado: (2023)

Long-term proton pump inhibitors use and its association with premalignant gastric lesions: a systematic review and meta-analysis
por: Zheng, Zeyi, et al.
Publicado: (2023)

Adipose Stromal Cell-Secretome Counteracts Profibrotic Signals From IPF Lung Matrices
por: Vasse, Gwenda F., et al.
Publicado: (2021)

IPF clinical trial design and endpoints
por: Nathan, Steven D., et al.
Publicado: (2014)

Proton Pump Inhibitor and Tacrolimus Uses are Associated With Hypomagnesemia in Connective Tissue Disease: a Potential Link With Renal Dysfunction and Recurrent Infection
por: Hanaoka, Hironari, et al.
Publicado: (2021)

Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model
por: Nelson, Christina, et al.
Publicado: (2017)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
por: Barratt, Shaney L., et al.
Publicado: (2018)

Quantification of Lung Fibrosis in IPF-Like Mouse Model and Pharmacological Response to Treatment by Micro-Computed Tomography
por: Ruscitti, Francesca, et al.
Publicado: (2020)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Effect of proton pump inhibitors on the risk of chronic kidney disease: A propensity score-based overlap weight analysis using the United Kingdom Biobank
por: Zhang, Xing-Yu, et al.
Publicado: (2022)

Terpenes as bacterial efflux pump inhibitors: A systematic review
por: Dias, Kaio Jefté Santos De Oliveira, et al.
Publicado: (2022)

Standard-Dose Proton Pump Inhibitors in the Initial Non-eradication Treatment of Duodenal Ulcer: Systematic Review, Network Meta-Analysis, and Cost-Effectiveness Analysis
por: Zhang, Jiaxing, et al.
Publicado: (2019)

Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: An updated meta-analysis
por: Zhao, Xianghong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o4cs0hlmhs2gjsk704ngqofrfl